Methodological issues of corticosteroid use in SLE clinical trials

Lupus

Volumn 8, Issue 8, 1999, Pages 692-697

  Corzillius, M ^a   Bae, S C ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b Hanyang University College of Medicine   (South Korea)

Author keywords

Clinical trials; Corticosteroids; SLE

Indexed keywords

CORTICOSTEROID;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MEDICAL LITERATURE; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDLINE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0032709943     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399680411407     Document Type: Article

References (32)

1. Gaubitz M, Seidel M, Kummer et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998; 11: 495-501.
2. Eros B, Geher P, Gomor B, Czeizel AE. Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy). Eur J Obstetr Gyn Reprod Biol 1998; 80: 75-78.
3. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F. Sosa-Munoz J, Miranda JM, Jara U. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998; 7: 414-419.
4. Tsakonas B, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80-85.
5. Pallis M, Lim KL, Gardner-Medwin JM, Robins RA, Powell RJ. Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus. Lupus 1997; 6: 379-384.
6. McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-Al (340-440 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996; 5: 269-274.
7. Austin JS, Maisiak RS, Macrina DM, Heck LW. Health outcome improvements in patients with systemic lupus erythematosus using two telephone counseling interventions. Arthritis Care Res 1996; 9: 391-399.
8. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996; 101: 576-583.
9. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5: 237-241.
10. Maisiak R, Austin JS, West SG, Heck L. The effect of person-centered counseling on the psychological status of persons with systemic lupus erythematosus or rheumatoid arthritis: a randomized, controlled trial. Arthritis Care Res 1996; 9: 60-66.
11. Van Vollenhoven RE, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826-1831.
12. Daltroy LH, Robb-Nicholson C, Iversen MD, Wright BA, Liang MH. Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease. Br J Rheumatol 1995; 34: 1064-1069.
13. Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
14. Hackshaw KV, Shi Y, Brandwein SR, Jones K, Westcott JY. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. J Rheum 1995; 22: 462-468.
15. Peretz A, Cantinieaux B, Neve J, Siderova V, Fondu P. Effects of zinc supplementation on the phagocytic functions of polymorphonuclears in patients with inflammatory rheumatic diseases. J Trace Electrolyte 1994; 8: 189-194.
16. Adachi J, Cranney A, Goldsmith CH et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheum 1994; 21: 1922-1926.
17. Williams HJ, Egger MJ, Singer JZ et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheum 1994; 21: 1457-1462.
18. Euler HI-I, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Ann Med Int 1994; 145: 296-302.
19. Denburg SD, Carbolic RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1311-1320.
20. Scudeletti M, Puppo F, Lanza L et al. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. Eur J Chin Pharmacol 1993; 45(Suppl 1): S29-S34.
21. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow YE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Int Med 1993; 119: 366-369.
22. Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstetrics Gyn 1993; 81: 327-331.
23. Euler HH, Schroeder JO, Zeuner RA, Teske B. A randomised trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. Int J Artificial Organs 1991; 14: 639-646.
24. Walton Al, Snaith ML, Locniskar M, Cumberland AG, Morrow WJ, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 463-466.
25. Clark WE, Dau PC, Euler HH et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). J Clin Apheresis 1991; 6: 40-47.
26. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
27. Chee YC. The mega shot. Singapore Med J 1990; 31: 15-16.
28. Albert DA, Hadler NH, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 1979; 22: 945-954.
29. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Int Med 1976; 84: 304-150.
30. Dixon RB, Christy NP. On the various forms of corticoid withdrawal syndrome. Am J Med 1980; 68: 224-229.
31. Weinstein MC. Allocation of subjects in medical experiments. N Engl J Med 1974; 291: 1278-1285 .
32. Altman D, Dore CJ. Randomization and baseline comparisons in clinical trials. Lancet 1985; 335: 149-155.